Vernal Keratoconjunctivitis - Pipeline Insight, 2024

This “Vernal Keratoconjunctivitis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vernal Keratoconjunctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vernal Keratoconjunctivitis Understanding

Vernal Keratoconjunctivitis: Overview

Vernal Keratoconjunctivitis (VKC) is a relatively rare, chronic form of ocular allergy that can potentially cause severe visual complications. Affecting mainly children and young adults, it is an IgE- and T cell-mediated disease, leading to a chronic inflammation in which eosinophil, lymphocyte and structural cell activation are involved. Treatment of VKC requires a multiple approach that includes conservative measures and pharmacologic treatment. Signs and symptoms usually begin before 10 years of age and may include hard, cobblestone-like bumps (papillae) on the upper eyelid; sensitivity to light; redness; sticky mucus discharge; and involuntary blinking or spasms of the eyelid. Management focuses on preventing flare ups and relieving the symptoms of the condition. It is often recommended that affected individuals try to avoid the agent that causes the allergy (if possible); wear dark sunglasses in the daytime; avoid dust; and stay inside on hot afternoons. Topical eye drops are generally preferred as the first source of treatment. Cold compresses, artificial tears, ointments and/or topical antihistamines may help. Non-steroid anti-inflammatory drugs (NSAIDS) may relieve symptoms in moderate cases; topical steroids are typically only used for more severe cases because long-term use can cause glaucoma.

Vernal Keratoconjunctivitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vernal Keratoconjunctivitis pipeline landscape is provided which includes the disease overview and Vernal Keratoconjunctivitis treatment guidelines. The assessment part of the report embraces, in depth Vernal Keratoconjunctivitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vernal Keratoconjunctivitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vernal Keratoconjunctivitis R&D. The therapies under development are focused on novel approaches to treat/improve Vernal Keratoconjunctivitis.

Vernal Keratoconjunctivitis Emerging Drugs Chapters

This segment of the Vernal Keratoconjunctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vernal Keratoconjunctivitis Emerging Drugs

iCo-008: iCo Therapeutics Bertilimumab is a fully human monoclonal antibody with specificity for human eotaxin-1 and inhibits its function. Favourable results from pre-clinical assessments resulted in three clinical studies of bertilimumab conducted in EU (a total of 126 patients - healthy individuals, patients with a history of seasonal allergic rhinitis and individuals with a history of seasonal allergic conjunctivitis) provided evidence of good safety and tolerability of bertilimumab when administered by the intravenous (IV) or intranasal route as well as topical application to the eye. A Phase II clinical trial for patients with vernal keratoconjunctivitis and/or atopic keratoconjunctivitis (involving cornea and conjunctiva) is in preparation.

Vernal Keratoconjunctivitis: Therapeutic Assessment

This segment of the report provides insights about the different Vernal Keratoconjunctivitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Vernal Keratoconjunctivitis

There are approx. 5+ key companies which are developing the therapies for Vernal Keratoconjunctivitis. The companies which have their Vernal Keratoconjunctivitis drug candidates in the most advanced stage, i.e. Phase II include, iCo Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Vernal Keratoconjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vernal Keratoconjunctivitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vernal Keratoconjunctivitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vernal Keratoconjunctivitis drugs.

Vernal Keratoconjunctivitis Report Insights

• Vernal Keratoconjunctivitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vernal Keratoconjunctivitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vernal Keratoconjunctivitis drugs?
• How many Vernal Keratoconjunctivitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vernal Keratoconjunctivitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vernal Keratoconjunctivitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vernal Keratoconjunctivitis and their status?
• What are the key designations that have been granted to the emerging drugs?